4,617
Views
4
CrossRef citations to date
0
Altmetric
Research Paper

BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes

, , , , , , , , , , , , , , , , , , , , ORCID Icon & show all
Pages 1-15 | Received 23 May 2022, Accepted 06 Sep 2022, Published online: 28 Sep 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Li Ma, Jianwei Wang, Yang Yang, Jun Lu, Jing Ling, Xinran Chu, Zimu Zhang, Yanfang Tao, Xiaolu Li, Yuanyuan Tian, Zhiheng Li, Yongping Zhang, Xu Sang, Lihui Lu, Xiaomei Wan, Kunlong Zhang, Yanling Chen, Juanjuan Yu, Ran Zhuo, Shuiyan Wu, Jian Pan, Xiuxia Zhou, Yixin Hu & Shaoyan Hu. (2023) BRD4 PROTAC degrader MZ1 exhibits anti-B-cell acute lymphoblastic leukemia effects via targeting CCND3. Hematology 28:1.
Read now

Articles from other publishers (2)

Bryony G. Kennedy, Jonathan J. Morgan & Lisa J. Crawford. (2023) Ubiquitin‐dependent regulation of MYC: A promising therapeutic target. Clinical and Translational Discovery 3:2.
Crossref
Lara J. Bou Malhab, Habiba Alsafar, Saleh Ibrahim & Mohamed Rahmani. (2023) PROTACs: Walking through hematological malignancies. Frontiers in Pharmacology 14.
Crossref